Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +55

Amgen stock edges toward analyst targets on solid fundamentals

AI-generated analysis

📈 Amgen stock closed at USD 385.65 on September 18, 2026, trading just below the average analyst target of USD 387.69.

💰 The company reported strong earnings momentum with recent quarters beating market expectations, driving a 1.55% share price increase.

🎯 Analyst targets range from a low of USD 225.00 to a high of USD 457.00, indicating potential upside beyond the current valuation.

📊 Amgen shares have gained approximately 17.82% since the start of 2026, reflecting sustained positive market sentiment.

💵 The company holds an A- grade for dividend growth, signaling a strong track record of increasing payouts to shareholders.

🏢 With a market capitalization of roughly USD 208.45 billion, Amgen remains a major constituent in the global biotechnology space.

Bullish Signals
  • Amgen stock recently closed at USD 385.65, trading just below the average analyst target of USD 387.69, signaling confidence from Wall Street analysts.
  • The company has reported strong earnings momentum in recent quarters with consistent beats versus market expectations, driving a positive 1.55% share price move.
  • Amgen holds an A- grade for dividend growth, demonstrating a robust history of increasing payouts that appeals to income-oriented investors.
  • The stock has gained approximately 17.82% since the start of 2026, indicating sustained investor confidence in its fundamental performance.
Full Analysis
Amgen stock recently closed at USD 385.65 on the Nasdaq on September 18, 2026, positioning it just below the average analyst target price of approximately USD 387.69. The company has demonstrated strong earnings momentum in recent quarters, consistently beating market expectations and driving a positive market reaction that saw shares rise around 1.55% following the latest session. Analyst consensus data compiled around mid-September 2026 indicates that while the current price leaves limited immediate upside from the average target, there remains significant potential for growth relative to the high analyst objective of USD 457.00. The stock has gained roughly 17.82% since the start of 2026, reflecting investor confidence in its earnings trajectory and solid fundamental performance within the large-cap healthcare sector. Beyond earnings beats, Amgen benefits from a robust history of dividend growth, earning an A- grade for dividend growth alongside peers like AbbVie. This consistent payout track record makes the stock attractive to income-oriented investors, while the company maintains a substantial market capitalization of approximately USD 208.45 billion as of September 21, 2026.